Raha Shahroodi

Deardorff WJ, Jing B, Growdon ME, Yaffe K, Boscardin WJ, Boockvar KS, Steinman MA. Medication misuse and overuse in community-dwelling persons with dementia. J Am Geriatr Soc. 2023 Jun 5. doi: 10.1111/jgs.18463. Epub ahead of print. PMID: 37272899. The study by Deardorff et al. investigated medication misuse and overuse within the community-dwelling older adult population […]

Etherton-Beer C, Page A, Naganathan V, Potter K, Comans T, Hilmer SN, McLachlan AJ, Lindley RI, Mangin D. Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial-outcomes of the Opti-med study. Age Ageing. 2023 May 1;52(5):afad081. doi: 10.1093/ageing/afad081. PMID: 37247404; PMCID: PMC10226731. The Opti-med study, conducted between 2014 and

Thomas C, Ellison H, Taffet GE. Deprescribing statins, considerations for informed decision making. J Am Geriatr Soc. 2023 Apr 21. doi: 10.1111/jgs.18362. Epub ahead of print. PMID: 37082816. To address ongoing uncertainties in deprescribing statins, Thomas et al. authored a commentary that explores key considerations and cautions when stopping these medications. Deprescribing aims to manage

Vasilevskis EE, Shah AS, Hollingsworth EK, et al. Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial. JAMA Intern Med. 2023;183(3):223-231. doi:10.1001/jamainternmed.2022.6545 Despite the well-known risks of polypharmacy among hospitalized older adults, few deprescribing interventions target initiating deprescribing in the hospital, and to date no deprescribing trial

Hung A, Wang J, Moriarty F, et al. Value assessment of deprescribing interventions: Suggestions for improvement [published online ahead of print, 2023 Feb 21]. J Am Geriatr Soc. 2023;10.1111/jgs.18298. doi:10.1111/jgs.18298 Despite the well-established link between deprescribing interventions and reduced use of potentially inappropriate medications (PIMs), there is little evidence behind the cost-effectiveness of these interventions.

Sheehan OC, Gleason KS, Bayliss EA, et al. Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trial [published online ahead of print, 2022 Dec 12]. J Am Geriatr Soc. 2022;10.1111/jgs.18148. doi:10.1111/jgs.18148 Polypharmacy is a growing concern among older adults, especially those with cognitive impairment and Multiple Chronic Conditions (MCC). Cognitively impaired

Kwak MJ, Cheng M, Goyal P, et al. Medication Complexity Among Older Adults with HF: How Can We Assess Better?. Drugs Aging. 2022;39(11):851-861. doi:10.1007/s40266-022-00979-2 Heart failure affects 6 million Americans today, over half of whom are 75 and older. Older adults with heart failure face complex medication regimens that are further complicated by the cognitive,

Wang J, Shen JY, Conwell Y, et al. How “age-friendly” are deprescribing interventions? A scoping review of deprescribing trials [published online ahead of print, 2022 Oct 11]. Health Serv Res. 2022;10.1111/1475-6773.14083. doi:10.1111/1475-6773.14083 The 4Ms (“Medication,” “Mentation,” “Mobility,” and “What Matters Most”) are considered essential components of age-friendly health systems. Age-friendly health systems are better equipped

Pilla SJ, Meza KA, Schoenborn NL, Boyd CM, Maruthur NM, Chander G. A Qualitative Study of Perspectives of Older Adults on Deintensifying Diabetes Medications [published online ahead of print, 2022 Sep 29]. J Gen Intern Med. 2022;10.1007/s11606-022-07828-3. doi:10.1007/s11606-022-07828-3 While previous studies have examined the patient perspective on deprescribing, few have explored this topic in relation